BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27543619)

  • 21. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
    Salagierski M; Schalken JA
    J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
    Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
    Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
    Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
    BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seminal fluid: a useful source of prostate cancer biomarkers?
    Roberts MJ; Richards RS; Gardiner RA; Selth LA
    Biomark Med; 2015; 9(2):77-80. PubMed ID: 25689895
    [No Abstract]   [Full Text] [Related]  

  • 27. ERG protein expression as a biomarker of prostate cancer.
    Falzarano SM; Magi-Galluzzi C
    Biomark Med; 2013 Dec; 7(6):851-65. PubMed ID: 24266818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
    Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
    Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
    Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
    Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simple, rapid, low-cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA.
    Koo KM; Wee EJ; Mainwaring PN; Trau M
    Sci Rep; 2016 Jul; 6():30722. PubMed ID: 27470540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary Biomarkers for Prostate Cancer.
    Tosoian JJ; Ross AE; Sokoll LJ; Partin AW; Pavlovich CP
    Urol Clin North Am; 2016 Feb; 43(1):17-38. PubMed ID: 26614026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
    Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
    Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
    Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
    Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
    Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.
    Berg KD; Vainer B; Thomsen FB; Røder MA; Gerds TA; Toft BG; Brasso K; Iversen P
    Eur Urol; 2014 Nov; 66(5):851-60. PubMed ID: 24630684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated fatty acid synthase expression in prostate needle biopsy cores predicts upgraded Gleason score in radical prostatectomy specimens.
    Hamada S; Horiguchi A; Kuroda K; Ito K; Asano T; Miyai K; Iwaya K
    Prostate; 2014 Jan; 74(1):90-6. PubMed ID: 24108439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffusion Kurtosis Imaging Helps to Predict Upgrading in Biopsy-Proven Prostate Cancer With a Gleason Score of 6.
    Wu CJ; Zhang YD; Bao ML; Li H; Wang XN; Liu XS; Shi HB
    AJR Am J Roentgenol; 2017 Nov; 209(5):1081-1087. PubMed ID: 28834443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.